The effect of risankizumab on achieving minimal clinically important differences in patient‐reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2

BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory disease that reduces the quality of life. This study assessed the effects of risankizumab (RZB) on the achievement of minimal clinically important differences (MCID) in patient‐reported outcomes (PROs). METHODS: KEEPsAKE‐1 and ‐2 are ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristensen, L.E., Soliman, A.M., Papp, K., Barcomb, L., Eldred, A., Östör, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828059/
https://www.ncbi.nlm.nih.gov/pubmed/35920763
http://dx.doi.org/10.1111/jdv.18475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828059/
https://www.ncbi.nlm.nih.gov/pubmed/35920763
http://dx.doi.org/10.1111/jdv.18475

Ejemplares similares